New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
06:36 EDTNBIXNeurocrine Biosciences initiated with a Buy at Lazard Capital
Target $13.
News For NBIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2015
07:12 EDTNBIXNeurocrine coverage assumed with a Buy at Jefferies
Jefferies assumed coverage on Neurocrine with a Buy rating and increased its price target to $61 from $39. The firm expects Neurocrine Phase III data for elagolix and valbenazine over the next 6-9 months, to drive potential regulatory approval and market launch in 2017.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use